300858 Beijing Scitop Bio-tech
- 15.11
- +0.37+2.51%
Beijing Scitop Bio-tech News
Cotuo Biotech (300858.SZ) grants 2.6 million restricted shares at a grant price of 13 yuan/share
Ketuo Biotech (300858.SZ) announced that restricted shares stipulated in the company's 2024 restricted stock incentive plan...
Cotuo Biotech (300858.SZ) reported 2023 annual results, net profit of 93.4799 million yuan, a year-on-year decrease of 14.93%
Cotuo Biotech (300858.SZ) released its 2023 annual report, with revenue of 299 million yuan, a year-on-year decrease...
Cotuo Biotech (300858.SZ) plans to grant no more than 3 million restricted shares at a grant price of 13 yuan/share
Cotuo Biotech (300858.SZ) disclosed the 2024 Restricted Stock Incentive Plan (draft), and the company plans to promote...
Ketuo Biotech (300858.SZ): Some fund-raising projects to be postponed
Gelonghui, December 29, 丨 Ketuo Biotech (300858.SZ) announced that the company held the 4th meeting of the 3rd board of directors and the 4th meeting of the 3rd board of supervisors on December 29, 2023 to review and pass the “Proposal on the Extension of Fund-raising Projects”, agreeing that the company will adjust the time when the fund-raising project implementation entity, implementation method, investment use and investment scale of the fund-raising project will not change. The bill does not need to be submitted to the company's shareholders' meeting for consideration. Although the feasibility of this fund-raising project was fully demonstrated in the early stages, it was actually implemented by many parties
Ketuo Biology (300858.SZ): Currently, there is no collaboration with Bacteria Xiaobao
Glonghui December 1: Some investors asked Ketuo Biotech (300858.SZ) on the investor interactive platform, “Is Yu Xiaobao a customer of your company?” The company replied that at present, the company has not cooperated with Bacteria Xiaobao.
Liu Xiaojun, shareholder of Ketuo Biotech (300858.SZ), terminated the holdings reduction plan early and did not reduce his holdings
Ketuo Biotech (300858.SZ) announced that as of November 21, 2023, the current holdings reduction plan is already...
Ketuo Biotech (300858.SZ): Plans to use no more than 500 million yuan of idle own funds for cash management
Glonghui, Oct. 24, 丨 Keto Biotech (300858.SZ) announced that on October 23, 2023, the company held the 3rd meeting of the 3rd board of directors and the 3rd meeting of the 3rd board of supervisors to deliberate and pass the “Proposal on Using Idle Own Funds for Cash Management”, agreeing that the company intends to use idle own funds totaling no more than RMB 500 million (including principal amount) for cash management without affecting the company's normal operation and capital safety. The above amount is valid for 12 months from the date of consideration and approval at the 2nd Extraordinary General Meeting of Shareholders in 2023. Within the limits and terms described above
Ketuo Biotech (300858.SZ): Net profit for the third quarter was 31672.99 million yuan, down 24.29% year-on-year
Glonghui, Oct. 24, Oct. 24 | Ketuo Biotech (300858.SZ) announced its report for the third quarter of 2023. Revenue for the reporting period was 77.0152 million yuan, down 28.19% year on year; net profit attributable to shareholders of listed companies was RMB 31672.99 million, down 24.29% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was RMB 288.309 million, down 26.29% year on year; basic earnings per share were 0.12 yuan.
Ketuo Biotech (300858.SZ): Probiotic products with optimal benefits are sports training bureau national team athletes preparation support products
Glonghui, September 26丨Ketuo Biotech (300858.SZ) said on the investor interactive platform that the company's probiotic benefits products are sports training bureau national team athletes preparation protection products.
Zhang Liebing, the main shareholder of Cotuo Biotech (300858.SZ), passively diluted and reduced his holdings by 1.04%
Coto Biotech (300858.SZ) announced that on June 13, 2022, the 2021 restrictions imposed by the company...
Sun Tiansong, the actual controller of Cotuo Biotech (300858.SZ), plans to transfer 16.84445 million shares to Lin Wei
Zhitong Finance App News, Ketuo Biotech (300858.SZ) announced that Sun Tiansong, the controlling shareholder and actual controller of the company, signed the “Share Transfer Agreement on Beijing Ketuo Hengtong Biotechnology Co., Ltd.” with Lin Wei on August 4, 2023. Sun Tiansong plans to transfer 16.84445 million unrestricted tradable shares of the company to Lin Wei through an agreement transfer, accounting for 6.3927% of the company's total share capital. The agreed transfer price is 13.01 yuan/share, with a total share transfer price of 219 million yuan.
Financial Report 2023 | Tying Mengniu to “Gains and Losses”: Cotuo Biotech's battle to get rid of dependency is in full swing
It's nice to cool off by leaning on a big tree, but there's no free lunch in the sky. On August 1, the semi-annual report released by Cotuo Biotech (300858SZ) showed that revenue and net profit for the first half of 2023 were 140 million yuan and 040 million yuan respectively, down 10.79% and 10.01% year-on-year respectively. One of the main reasons is the decline in revenue from compound food additives, which has impacted the performance of Cotto Biotech. In the first half of 2023, the main use of compound food additives generated revenue of 42 million yuan, a year-on-year decrease of 48.39%, accounting for 30% of revenue. “Compound food additives are passed down by the company
Cotuo Biotech (300858.SZ): Shareholder Liu Xiaojun terminated the holdings reduction plan ahead of schedule and plans to reduce holdings by no more than 1.268 million shares
On August 2, GLONGHUI | Cotuo Biotech (300858.SZ) announced that the company recently received the “Notice Letter on Early Termination of the Stock Holding Reduction Plan and the Follow-up Holding Reduction Plan” from shareholder Liu Xiaojun. Based on his own financial plan, Mr. Liu Xiaojun decided to adjust the holdings reduction arrangement, terminate the holdings reduction plan disclosed on January 6, 2023 ahead of schedule, and launch a new holdings reduction plan. During the holdings reduction period, it reduced its holdings by a total of 1,407.79 million shares, a reduction ratio of 0.8145%. The total number of shares that Liu Xiaojun plans to reduce in the future will not exceed 1,2679.98 million shares (if the company has a share transfer or capital provident fund during the holdings reduction period
The 72.70102 million restricted shares of Cotuo Biotech (300858.SZ) will be listed and circulated on July 31
According to the Zhitong Finance App, Ketuo Biotech (300858.SZ) announced that the number of shares currently lifted by the company is 132 million shares, accounting for 50.16% of the company's total share capital. The actual number of shares that can be listed and circulated is 72.70102 million shares, accounting for 27.59% of the company's total share capital. The listing and circulation date is July 31, 2023 (Monday).
The 38.1016 million restricted shares of Cotuo Biotech (300858.SZ) will be listed for circulation on July 18
According to the Zhitong Finance App, Ketuo Biotech (300858.SZ) announced that the number of shares currently lifted by the company is 38.1016 million shares, accounting for 14.46% of the company's total share capital. The listing and circulation date is July 18, 2023 (Tuesday).
Ketuo biology: 27 institutions, including Panwang Investment and Bank of China Samsung Life Insurance, investigated our company on January 7.
Ketuo Biology (300858) issued an announcement on January 9, 2022: Panshi Investment Wang Ze, Bank of China Samsung Life Zhou Jianming, Fang Zhengfu Bang Xiaxu, Pengyang Fund Wang Yiqin, Huaxia Fund Wang Shijia, Huian Fund Xu Zhijie, Oriental Fund Lu Yanchen, Societe Generale Fund Jiang Hanyu, Xitai Investment Feng Jiaan, Yi Mi Fund Liu Zechen, curious Asset Wan Xuefei, Hongcheng Investment Xiang Hongbo, Xinyang Fund Chen Jiecheng, Luo Pei Investment Sun thinking, Oriental Securities Xing Kai Li Wei, century-old insurance asset du Tianqi, Morgan Stanley Huaxin Fund Su Xiang, Kaifeng Investment Fan Huihua, Wuju Asset Wang Xin, Kaiyuan Fund Wang Jianwei, Red Chip Investment Cui Xin
Guohai Securities: give Ketuo biological increase rating
In 2022-01-07, Xue Yuhu and Liu Jieming of Guohai Securities Co., Ltd. studied Ketuo and released the research report "dynamic comments: domestic independent probiotic leader, future growth prospects". The current share price is 42.11 yuan. Ketuo Biology (300858) Investment points: the company has strong R & D strength, a number of star strains break the international monopoly, the growth rate of edible probiotics plate is eye-catching, and there is a broad space for domestic substitution. The revenue of the edible probiotics sector in the first three quarters of 2021 was 58 million yuan, an increase of 166.8 over the same period last year.
The latest announcement of Ketuo Biology: scientific experiments and clinical tests have been carried out on some of the efficacy of anti-Helicobacter pylori and relevant patents are being applied for.
Ketuo Biology issued a change announcement, the company found that the recent public media reported the concept of Helicobacter pylori, making the A-share secondary market pay more attention to the concept of "Helicobacter pylori". The company is a high-tech enterprise mainly engaged in R & D, production and sales of compound food additives, edible probiotic products and animal and plant microecological preparations. In recent years, the company has carried out scientific experiments and clinical tests on the anti-Helicobacter pylori efficacy of some core strains, and is applying for relevant patents. The chairman of the company is Sun Tiansong. Ms. Sun Tiansong: born in November 1967, Chinese nationality, no permanent residence outside the country, doctoral degree
January 6 Ketuo biological limit analysis: Helicobacter pylori concept, food concept hot stock
Ketuo Biological rose and closed with a closing price of 45.22 yuan. The stock rose by the daily limit at 09:37, opening the limit once, and the closing capital was 47.8328 million yuan, accounting for 1.99% of its current market value. In terms of capital flow data, the net inflow of main funds on the same day was 57.5538 million yuan, the net inflow of hot capital was 106 million yuan, and the net outflow of retail funds was 13.2555 million yuan. The flow of funds in the past 5 days is shown in the following table: the unit is a hot stock of Helicobacter pylori concept and food concept. On that day, Helicobacter pylori concept rose 6.02%, and food concept rose 0.83%. This article is based on the Securities Star data Center.
KuaiBao: Ketuo Biology (300858) sealed the trading limit at 10:34 on January 6th.
On January 6, intraday news, 10:34 Ketuo Biological (300858) sealed the trading limit. The current price is 45.22, up 20.01%. The main indicators and industry rankings of Ketuo Biology are as follows: Ketuo Biology (300858) Stock profile: this article is compiled by Securities Star data Center according to public data, and does not constitute investment opinions or suggestions. If you have any questions, please contact us.
Analysis
Price Target
No Data
